Table 1.

Clinicopathological patient characteristics.

Patient Characteristics		N (n = 37)	%
Age (years)	<50	15	40.5
(Median: 54 (31–76))	≥50	22	59.5
pTNM	Stage I	0	0.0
	Stage II	22	59.5
	Stage III	15	40.5
	Stage IV	0	0.0
Number of	1–3 (pN1)	17	45.9
metastatic lymph nodes	4–9 (pN2)	13	35.1
	≥10 (pN3)	7	18.9
Ki67 LI (%)	<20	28	75.7
	≥20	9	24.3
Histological Grade	1	4	10.8
(Primary tumor)	2	20	54.1
	3	4	10.8
Subtype	Luminal A	19	51.4
(Primary tumor)	Luminal B—HER2−	11	29.7
	Luminal B—HER2+	5	13.5
	HER2	0	0.0
	Triple negative	2	5.4
Regimen	Anthracycline	5	13.5
	Anthracycline + Taxane	27	73.0
	Anthracycline + Taxane + Trastuzumab	5	13.5
Pathological response	0	0	0.0
	1a	17	45.9
	1b	12	32.4
	2	8	21.6
	3	0	0.0